Resolution Therapeutics presents hopeful data on regenerative macrophage therapy for cirrhosis at AASLD 2025
Resolution Therapeutics has announced new data from its portfolio of macrophage-based therapies at the AASLD 2025 conference. The company highlighted early clinical signals from the MATCH Phase II study, which evaluate the potential of non-engineered macrophages to repair cirrhotic livers and improve patient outcomes. In addition, preliminary preclinical results from Resolution’s engineered macrophage platform were shared, underscoring a diversified approach to regenerative macrophage therapy for liver disease.
What the MATCH Phase II data show
The MATCH Phase II trial focuses on non-engineered macrophages designed to home to damaged liver tissue, promote regeneration, and modulate the inflammatory environment that drives fibrosis. Interim analyses indicate that patients receiving the macrophage therapy exhibit early improvements in liver function tests and composite biomarkers of liver injury and regeneration. Importantly, early functional gains appear to correlate with favorable longer-term clinical outcomes, suggesting the therapy may alter disease trajectory in cirrhosis when administered in a timely manner.
Resolution notes that these early signals are encouraging, particularly given the challenging biology of cirrhosis where scar tissue impedes normal liver function. The data emerged from a diverse trial population and included safety assessments demonstrating an acceptable tolerability profile to date. While longer follow-up is needed to confirm durability and impact on clinical endpoints such as decompensation events, portal hypertension, or transplant-free survival, the early improvements support the therapeutic hypothesis that regenerating liver tissue can be stimulated by macrophage-driven mechanisms.
Preclinical progress in engineered macrophage therapy
Beyond the non-engineered approach, Resolution shared initial preclinical data from its engineered macrophage program. Engineered cells are designed to enhance tissue targeting, secrete pro-regenerative factors, and more effectively reprogram inflammatory pathways within the liver. The preclinical results suggest potential synergy with the MATCH findings and a pathway to advancing second-generation products that could offer higher potency or broader applicability across stages of liver disease.
Company scientists emphasized that the engineered platform aims to complement the clinical insights from MATCH, addressing both the regenerative and immunomodulatory components of cirrhosis. These early preclinical signals lay the groundwork for upcoming translational studies and potential future clinical trials designed to test the safety and efficacy of engineered macrophages in patients with liver fibrosis and cirrhosis.
What these results mean for patients and the field
Regenerative macrophage therapy represents a novel therapeutic modality in hepatology, offering a mechanism to directly influence liver repair rather than merely slowing disease progression. If the positive associations observed in MATCH persist with longer follow-up and larger cohorts, this approach could become a cornerstone of disease-modifying treatment for cirrhosis. The combination of non-engineered macrophage data with engineered platform research also signals a robust pipeline that could address a spectrum of liver conditions in the coming years.
Next steps and outlook
Resolution Therapeutics plans continued enrollment in the MATCH Phase II study, with additional follow-up planned to assess durability of liver function gains and their relation to hard clinical outcomes. Parallel preclinical development of the engineered macrophage program will progress toward investigational new product readiness, including safety studies and scalable manufacturing processes. The company also indicated ongoing collaborations with academic and clinical centers to validate findings and refine patient selection criteria for regenerative macrophage therapy in cirrhosis.
About Resolution Therapeutics
Resolution Therapeutics is focused on regenerating liver tissue and altering the course of chronic liver diseases through macrophage-based therapies. The company’s strategy combines non-engineered macrophages that promote repair with engineered macrophage programs designed to amplify regenerative effects, aiming to deliver durable clinical benefits for patients with cirrhosis and related liver conditions.
